(Stroke. 2001;32:2947.)
© 2001 American Heart Association, Inc.
|
Comments, Opinions, and Reviews |
Emerging Therapies
Marc Fisher, MD, Section Editor Emerging Therapies
From the University of Massachusetts, Memorial Health Care, Worcester, Mass.
Correspondence to Dr Marc Fisher, University of Massachusetts, Memorial Health Care, 119 Belmont St, Worcester, MA 01605. E-mail fisherm@ummhc.org.
 |
Introduction
|
|---|
The critique of the CURE study written by Albers and Amarenco
represents the first contribution for the "Emerging Therapies"
section of
Stroke. In the future, timely invited critiques by
acknowledged experts of important and novel articles related
to stroke therapy will be provided to the readership. These
critiques will overview the results of the therapeutic studies
and provide expert commentary and interpretation. These endeavors
will hopefully enable the readership to better comprehend the
nuances and context of the study and utilize the results for
patient care. In addition to these critiques of major articles
in other journals related to stroke therapy, several in-depth
review articles per year will be sought. These review articles
will cover in detail a range of topics related to the gamut
of stroke therapies currently available and under development.
The intention of the review articles is to provide the readership
with a comprehensive, up-to-date, balanced, and detailed overview
of important and sometimes controversial stroke therapy topics.
Initial review articles of multimodality therapy to prevent
stroke, expanding the time window for thrombolytic therapy and
anticoagulation after acute stroke, are anticipated. Suggestions
for additional topics and authors are welcome. It is hoped that
the article critiques and reviews will add to the readerships
enjoyment of
Stroke and enhance their knowledge about emerging
stroke therapies.
 |
Footnotes
|
|---|
The opinions expressed in this editorial are not necessarily
those of the editor or of the American Stroke Association.